The many facets of metzincins and their endogenous inhibitors: Perspectives on ovarian cancer progression

Ruth M. Escalona, Emily Chan, George Kannourakis, Jock K. Findlay, Nuzhat Ahmed

Research output: Contribution to journalReview ArticleResearchpeer-review

3 Citations (Scopus)


Approximately sixty per cent of ovarian cancer patients die within the first five years of diagnosis due to recurrence associated with chemoresistance. The metzincin family of metalloproteinases is enzymes involved in matrix remodeling in response to normal physiological changes and diseased states. Recently, there has been a mounting awareness of these proteinases and their endogenous inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), as superb modulators of cellular communication and signaling regulating key biological processes in cancer progression. This review investigates the role of metzincins and their inhibitors in ovarian cancer. We propose that understanding the metzincins and TIMP biology in ovarian cancer may provide valuable insights in combating ovarian cancer progression and chemoresistance-mediated recurrence in patients.

Original languageEnglish
Article number450
Number of pages33
JournalInternational Journal of Molecular Sciences
Issue number2
Publication statusPublished - 2 Feb 2018
Externally publishedYes


  • ADAM proteases with thrombospondin motifs (ADAMTS)
  • Disintegrin and metalloproteinases (ADAMs)
  • Matrix metalloproteinases (MMPs)
  • Metastasis
  • Metzincins
  • Ovarian cancer
  • TIMPs

Cite this